Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,550 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies.
Kabashima K, Matsumura T, Komazaki H, Kawashima M; Nemolizumab JP01 andJP02 Study Group. Kabashima K, et al. Among authors: kawashima m. Br J Dermatol. 2022 Apr;186(4):642-651. doi: 10.1111/bjd.20873. Epub 2021 Dec 21. Br J Dermatol. 2022. PMID: 34726262 Free PMC article. Clinical Trial.
Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials.
Katoh N, Kataoka Y, Saeki H, Hide M, Kabashima K, Etoh T, Igarashi A, Imafuku S, Kawashima M, Ohtsuki M, Fujita H, Arima K, Takagi H, Chen Z, Shumel B, Ardeleanu M. Katoh N, et al. Among authors: kawashima m. Br J Dermatol. 2020 Jul;183(1):39-51. doi: 10.1111/bjd.18565. Epub 2019 Nov 28. Br J Dermatol. 2020. PMID: 31564057 Free PMC article.
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NM, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M. Thaçi D, et al. Among authors: kawashima m. Lancet. 2016 Jan 2;387(10013):40-52. doi: 10.1016/S0140-6736(15)00388-8. Epub 2015 Oct 8. Lancet. 2016. PMID: 26454361 Clinical Trial.
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
Worm M, Simpson EL, Thaçi D, Bissonnette R, Lacour JP, Beissert S, Kawashima M, Ferrándiz C, Smith CH, Beck LA, Chan KC, Chen Z, Akinlade B, Hultsch T, Staudinger H, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Ardeleanu M. Worm M, et al. Among authors: kawashima m. JAMA Dermatol. 2020 Feb 1;156(2):131-143. doi: 10.1001/jamadermatol.2019.3617. JAMA Dermatol. 2020. PMID: 31876900 Free PMC article. Clinical Trial.
[Pathogenesis and treatment of atopic dermatitis].
Kawashima M. Kawashima M. Nihon Rinsho Meneki Gakkai Kaishi. 1999 Dec;22(6):382-5. doi: 10.2177/jsci.22.382. Nihon Rinsho Meneki Gakkai Kaishi. 1999. PMID: 10726469 Review. Japanese. No abstract available.
1,550 results